Why AstraZeneca Topped the Market on Thursday
Werte in diesem Artikel
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as the stock closed the day more than 2% higher in value. This was notably better than the 0.4% bump of the S&P 500 index.AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 2023's figure. On the bottom line the company's "core" (i.e., non-GAAP) earnings per share rose even more sharply, advancing by 44% to $2.09. There was quite some distance between AstraZeneca's performance and analyst estimates for the quarter. On average, pundits following the company were anticipating it would post a lower revenue number ($14.15 billion) and a far lower adjusted net profit of $1.06 per share. Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf AstraZeneca
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: MotleyFool
Nachrichten zu AstraZeneca PLC
Analysen zu AstraZeneca PLC
Datum | Rating | Analyst | |
---|---|---|---|
26.03.2025 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
17.03.2025 | AstraZeneca Outperform | Bernstein Research | |
17.03.2025 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
17.03.2025 | AstraZeneca Buy | UBS AG | |
17.03.2025 | AstraZeneca Overweight | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
26.03.2025 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
17.03.2025 | AstraZeneca Outperform | Bernstein Research | |
17.03.2025 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
17.03.2025 | AstraZeneca Buy | UBS AG | |
17.03.2025 | AstraZeneca Overweight | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
12.02.2025 | AstraZeneca Hold | Deutsche Bank AG | |
07.02.2025 | AstraZeneca Halten | DZ BANK | |
07.02.2025 | AstraZeneca Hold | Deutsche Bank AG | |
06.02.2025 | AstraZeneca Neutral | UBS AG | |
06.02.2025 | AstraZeneca Hold | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
12.11.2024 | AstraZeneca Sell | UBS AG | |
07.11.2024 | AstraZeneca Sell | UBS AG | |
05.11.2024 | AstraZeneca Sell | UBS AG | |
05.11.2024 | AstraZeneca Sell | Deutsche Bank AG | |
05.11.2024 | AstraZeneca Sell | UBS AG |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AstraZeneca PLC nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen